Examination of changes in utilization, dose adequacy, and duration associated with market entry of the oral chelator deferasirox as a potential substitute for parenteral deferoxamine.
Maria R. Baer, MD
Advertisement
Articles by Maria R. Baer, MD
Advertisement
Latest Updated Articles
- Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies
Published: March 17th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
FDA Grants Orphan Drug Status to Immunotherapy for Acute Myeloid Leukemia Treatment
5
